Senvest Management, LLC Bio Line Rx Ltd. Transaction History

Senvest Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$1.47 - $3.62 $486,871 - $1.2 Million	-331,205 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$1.56 - $2.37 $187,200 - $284,400	-120,000 Reduced 26.6%	331,205 $543,000
Q2 2020 Aug 13, 2020	SELL	$1.23 - $2.39 $89,315 - $173,547	-72,614 Reduced 13.86%	451,205 $772,000
Q1 2020 May 14, 2020	SELL	$1.11 - $2.6 $116,264 - $272,331	-104,743 Reduced 16.66%	523,819 $697,000
Q4 2019 Feb 13, 2020	BUY	$1.97 - $2.97 $248,170 - $374,145	125,975 Added 25.07%	628,562 $1.41 Million
Q3 2019 Nov 13, 2019	BUY	$2.56 - $5.25 $1.29 Million - $2.64 Million	502,587 New	502,587 $1.33 Million

3.35M

46.5K

6.3K

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $13.5M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

Get notified when there are updates to the investment portfolio of Senvest Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Senvest Management, LLC with notifications on news.